Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | ADH5 | P11766 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perchlorate SCHEMBL6368227 | 0.95 | CYP3A4 (0.45) | CYP3A4BAZ2BHTR2AHTR2CHTR2B | |
| SCHEMBL17319234 | 0.81 | GAA (0.65) | CYP3A4BAZ2BHTR2AHTR2CHTR2B | |
| SCHEMBL6324442 | 0.77 | CHRNA7 (0.47) | CYP3A4BAZ2BHTR2AHTR2CHTR2B | |
| SCHEMBL6336383 | 0.76 | CHRNA7 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| SCHEMBL9257879 | 0.76 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| SCHEMBL8711485 | 0.76 | PAX8 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL6319408 | 0.76 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4HTT | |
| Hydrochloric Acid SCHEMBL9272008 | 0.75 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL9269412 | 0.73 | CRHBP (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4HTT | |
| SCHEMBL9363641 | 0.73 | HPGD (0.68) | CYP3A4BAZ2BHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887881-B1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | US | disclosed |
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1047695-B1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1192154-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1192156-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1192155-B1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| US-6465481-B1 | EXHIBIT ELECTROPHYSIOLOGICAL ACTIVITY; MAY BE MORE POTENT AND PRODUCE FEWER SIDE EFFECTS INCLUDING LOWER INCIDENCE OF PROARRHYTHMIAS SUCH AS TORSADES DE POINTES | ASTRAZENECA AB (SE) | 2002-10-15 | — | — | US | disclosed |
| US-6291475-B1 | 3,7-DIAZABICYCLO(3.3.1)NONANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-1114154-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | Genentech, Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1086063-A4 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1086063-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064050-A9 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-2000015797-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | GENENTECH, INC. (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5468858-A | Sudden death syndrome | THE BOARD OF REGENTS OF OKLAHOMA STATE UNIVERSITY PHYSICAL SCIENCES (US) | 1995-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | CYP3A4 120/4885BAZ2B 2731/4885HTR2A 293/4885 |
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | CYP3A4 179/4885BAZ2B 2811/4885HTR2A 537/4885 |
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | DRD2, ADRA1D, KCND2 | CYP3A4 274/4885BAZ2B 967/4885HTR2A 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.